TY - JOUR
T1 - A live attenuated strain of Yersinia pestis KIM as a vaccine against plague
AU - Sun, Wei
AU - Six, David
AU - Kuang, Xiaoying
AU - Roland, Kenneth L.
AU - Raetz, Christian R H
AU - Curtiss, Roy
N1 - Funding Information:
We thank Dr. Susan Straley for providing anti-YopM antibodies and Dr. Praveen Alamuri for his valuable assistance in performing animal experiments.Conflict of interest: All authors declare none. Funding: This work was supported by National Institutes of Health grant 5R01 AI057885 to R. C. and by grant GM51310 to C. R. H. R. The mass spectrometry facility in the Department of Biochemistry of the Duke University Medical Center is supported by the LIPID MAPS Large Scale Collaborative Grant number GM-069338 from NIH.
PY - 2011/4/5
Y1 - 2011/4/5
N2 - Yersinia pestis, the causative agent of plague, is a potential weapon of bioterrorism. Y. pestis evades the innate immune system by synthesizing tetra-acylated lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity at 37°C, whereas hexa-acylated lipid A, a potent TLR4 agonist, is made at lower temperatures. Synthesis of Escherichia coli LpxL, which transfers the secondary laurate chain to the 2'-position of lipid A, in Y. pestis results in production of hexa-acylated lipid A at 37°C, leading to significant attenuation of virulence. Previously, we described a Y. pestis vaccine strain in which crp expression is under the control of the arabinose-regulated araC PBAD promoter, resulting in a 4-5 log reduction in virulence. To reduce the virulence of the crp promoter mutant further, we introduced E. coli lpxL into the Y. pestis chromosome. The χ10030(pCD1Ap) (ΔlpxP32::PlpxL lpxL ΔPcrp21::TT araC PBAD crp) construct likewise produced hexa-acylated lipid A at 37°C and was significantly more attenuated than strains harboring each individual mutation. The LD50 of the mutant in mice, when administered subcutaneously or intranasally was >107-times and >104-times greater than wild type, respectively. Mice immunized subcutaneously with a single dose of the mutant were completely protected against a subcutaneous challenge of 3.6×107 wild-type Y. pestis and significantly protected (80% survival) against a pulmonary challenge of 1.2×104 live cells. Intranasal immunization also provided significant protection against challenges by both routes. This mutant is an immunogenic, highly attenuated live Y. pestis construct that merits further development as a vaccine candidate.
AB - Yersinia pestis, the causative agent of plague, is a potential weapon of bioterrorism. Y. pestis evades the innate immune system by synthesizing tetra-acylated lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity at 37°C, whereas hexa-acylated lipid A, a potent TLR4 agonist, is made at lower temperatures. Synthesis of Escherichia coli LpxL, which transfers the secondary laurate chain to the 2'-position of lipid A, in Y. pestis results in production of hexa-acylated lipid A at 37°C, leading to significant attenuation of virulence. Previously, we described a Y. pestis vaccine strain in which crp expression is under the control of the arabinose-regulated araC PBAD promoter, resulting in a 4-5 log reduction in virulence. To reduce the virulence of the crp promoter mutant further, we introduced E. coli lpxL into the Y. pestis chromosome. The χ10030(pCD1Ap) (ΔlpxP32::PlpxL lpxL ΔPcrp21::TT araC PBAD crp) construct likewise produced hexa-acylated lipid A at 37°C and was significantly more attenuated than strains harboring each individual mutation. The LD50 of the mutant in mice, when administered subcutaneously or intranasally was >107-times and >104-times greater than wild type, respectively. Mice immunized subcutaneously with a single dose of the mutant were completely protected against a subcutaneous challenge of 3.6×107 wild-type Y. pestis and significantly protected (80% survival) against a pulmonary challenge of 1.2×104 live cells. Intranasal immunization also provided significant protection against challenges by both routes. This mutant is an immunogenic, highly attenuated live Y. pestis construct that merits further development as a vaccine candidate.
KW - Lipid A
KW - Plague vaccine
KW - Regulated delayed attenuation
KW - Yersinia pestis
UR - http://www.scopus.com/inward/record.url?scp=79953231573&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953231573&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2011.01.099
DO - 10.1016/j.vaccine.2011.01.099
M3 - Article
C2 - 21320544
AN - SCOPUS:79953231573
SN - 0264-410X
VL - 29
SP - 2986
EP - 2998
JO - Vaccine
JF - Vaccine
IS - 16
ER -